OrbiMed Advisors LLC's Form 4 filing
Shattuck Labs, Inc. (STTK) · filed Sep 2, 2025
- Accession no.
- 0000947871-25-000840
- Filed
- Sep 2, 2025, 9:52 PM ET
- Trade date
- Aug 25, 2025
- Filing delay
- 8 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market purchases total $5.47M. It was filed 8 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director |
| OrbiMed Genesis GP LLCCIK 0001808744 | Director |
| OrbiMed Capital GP IX LLCCIK 0001920574 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2025 | Common Stock | PPurchaseAcquired | +5,255,106 | $0.8677 | +$4,559,855.48 | 5,255,106 | Indirect | |
| Aug 25, 2025 | Common Stock | PPurchaseAcquired | +1,051,021 | $0.8677 | +$911,970.92 | 1,051,021 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2025 | Common Stock | PPurchaseAcquired | +10,111,384 | –F1 | – | 10,111,384 | Indirect | Duplicate filing |
| Aug 25, 2025 | Common Stock | PPurchaseAcquired | +2,022,277 | –F1 | – | 2,022,277 | Indirect | Duplicate filing |
| Aug 25, 2025 | Common Stock | PPurchaseAcquired | +15,366,490 | –F1 | – | 15,366,490 | Indirect | Duplicate filing |
| Aug 25, 2025 | Common Stock | PPurchaseAcquired | +3,073,298 | –F1 | – | 3,073,298 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the "Closing Date") an aggregate of 6,306,127 shares of the Issuer's common stock ("Shares") and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676.
Referenced by the price of 4 transactions in Table II.